Lamotrigine Tablet, Extended Release
Product Images NDC 62332-418

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 62332-418). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Tablets Bottle Label (Lamotrigine 200mg)

Label for Lamotrigine Extended-Release Tablets USP 200 mg by Alembic Pharmaceuticals Inc. The label states it contains 30 tablets, with instructions about dosage, storage temperature, and seal warnings. It includes a barcode, lot number, and expiration date. The label emphasizes pharmacist instructions and medication guide dispensing.*

FDA Label Image

30 Tablets Bottle Label (Lamotrigine 250mg)

The label for Lamotrigine Extended-Release Tablets, USP 250 mg, shows it is an oral extended-release tablet manufactured by Alembic Pharmaceuticals Inc. The label includes dosage form, strength, quantity of 30 tablets, storage instructions, and warnings including a caution to verify product dispensing. The NDC number 62332-418-30 and barcode are also visible.*

FDA Label Image

30 Tablets Bottle Label (Lamotrigine 300mg)

Lamotrigine Extended-Release Tablets, USP 300 mg oral tablets, packaged in a bottle of 30 tablets. Labeler is Alembic Pharmaceuticals Inc. Instructions include storing at 25°C with permitted excursions, caution about seal integrity, and pharmacist dispensing directions. The label displays the NDC 62332-419-30 and lot/expiry information area.*

FDA Label Image

Lamotrigine Description (Lamotrigine Description 1)

Lamotrigine extended-release tablets in three strengths and colors: 200 mg blue tablet with imprint 'A196', 250 mg purple tablet with imprint 'A197', and 300 mg grey tablet with imprint 'A198' from Alembic Pharmaceuticals Inc.*

FDA Label Image

Figure 1 (Lamotrigine Figure1)

A responder rate curve chart comparing Lamotrigine Extended-Release Tablets (solid line) to Placebo (dashed line) in terms of improvement or worsening. The x-axis shows percent of patients from 100 to 0, and the y-axis shows responder rate from -100% (worsening) to 100% (improvement). The graph visualizes patient response distribution for both groups.*

FDA Label Image

Figure 2 (Lamotrigine Figure2)

A responder rate plot showing the percentage of patients versus responder rate for Lamotrigine Extended-Release Tablets compared to placebo. The y-axis represents responder rate from worsening (-100%) to improvement (100%), and the x-axis shows percent of patients. Two lines illustrate response rates for placebo (dashed line, N=120) and Lamotrigine Extended-Release Tablets (solid line, N=116).*

FDA Label Image

Structure (Lamotrigine Structure)

Chemical structure of lamotrigine, showing its molecular arrangement including chlorine atoms, nitrogen-containing rings, and amino groups, consistent with the structure of this anticonvulsant drug.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.